||||||||||MYTX-011 / Mythic Therap MYTX-011: A novel cMET-targeting antibody drug conjugate (ADC) engineered to increase on-target uptake in and efficacy against cMET expressing tumors (Section 17; Poster Board #13) - Mar 14, 2023 - Abstract #AACR2023AACR_7176; PK and toxicity studies in cynomolgus monkeys revealed that MYTX-011 exhibited favorable PK characteristics, and a toxicity profile similar to previously described MMAE-based ADCs. Together, these findings highlight the potential of MYTX-011 as a therapeutic candidate for treating a broader range of cMET+ malignancies than other cMET-ADCs.
||||||||||MYTX-011 / Mythic Therap Enrollment open: KisMET-01: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 10, 2023 P1, N=150, Recruiting, Sponsor: Mythic Therapeutics Together, these findings highlight the potential of MYTX-011 as a therapeutic candidate for treating a broader range of cMET+ malignancies than other cMET-ADCs. Not yet recruiting --> Recruiting